PL365854A1 - Sposoby leczenia zaburzeń czynności seksualnych zzastosowaniem apomorfiny w ilości zapewniającej określone poziomy stężeń osoczowych - Google Patents

Sposoby leczenia zaburzeń czynności seksualnych zzastosowaniem apomorfiny w ilości zapewniającej określone poziomy stężeń osoczowych

Info

Publication number
PL365854A1
PL365854A1 PL01365854A PL36585401A PL365854A1 PL 365854 A1 PL365854 A1 PL 365854A1 PL 01365854 A PL01365854 A PL 01365854A PL 36585401 A PL36585401 A PL 36585401A PL 365854 A1 PL365854 A1 PL 365854A1
Authority
PL
Poland
Prior art keywords
apomorphine
methods
plasma concentration
sexual dysfunction
concentration levels
Prior art date
Application number
PL01365854A
Other languages
English (en)
Inventor
Pramod K. Gupta
John Daniel Bollinger
Yisheng Chen
Jack Yuqun Zheng
Thomas L. Reiland
Dennis Y. Lee
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of PL365854A1 publication Critical patent/PL365854A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PL01365854A 2000-03-20 2001-03-14 Sposoby leczenia zaburzeń czynności seksualnych zzastosowaniem apomorfiny w ilości zapewniającej określone poziomy stężeń osoczowych PL365854A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19054000P 2000-03-20 2000-03-20

Publications (1)

Publication Number Publication Date
PL365854A1 true PL365854A1 (pl) 2005-01-10

Family

ID=22701756

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365854A PL365854A1 (pl) 2000-03-20 2001-03-14 Sposoby leczenia zaburzeń czynności seksualnych zzastosowaniem apomorfiny w ilości zapewniającej określone poziomy stężeń osoczowych

Country Status (18)

Country Link
US (1) US20020006933A1 (pl)
EP (1) EP1265609A4 (pl)
JP (1) JP2003533441A (pl)
KR (1) KR20030012852A (pl)
CN (1) CN1315177A (pl)
AU (1) AU2001253854A1 (pl)
BG (1) BG107185A (pl)
BR (1) BR0005797A (pl)
CA (1) CA2403791A1 (pl)
CZ (1) CZ20023427A3 (pl)
HU (1) HUP0301828A3 (pl)
IL (1) IL151615A0 (pl)
MX (1) MXPA02009237A (pl)
NO (1) NO20024442L (pl)
PL (1) PL365854A1 (pl)
SK (1) SK15112002A3 (pl)
WO (1) WO2001074358A1 (pl)
ZA (1) ZA200207113B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US7591999B2 (en) * 2003-03-04 2009-09-22 Mitsubishi Tanabe Pharma Corporation Powdery preparation for nasal administration
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CN104349768B (zh) * 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
WO2014205031A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
CN1315177A (zh) 2001-10-03
NO20024442L (no) 2002-11-20
EP1265609A4 (en) 2005-02-09
WO2001074358A1 (en) 2001-10-11
US20020006933A1 (en) 2002-01-17
HUP0301828A2 (hu) 2003-09-29
IL151615A0 (en) 2003-04-10
NO20024442D0 (no) 2002-09-17
ZA200207113B (en) 2004-01-28
BR0005797A (pt) 2001-10-16
MXPA02009237A (es) 2004-04-05
KR20030012852A (ko) 2003-02-12
CA2403791A1 (en) 2001-10-11
SK15112002A3 (sk) 2003-06-03
JP2003533441A (ja) 2003-11-11
AU2001253854A1 (en) 2001-10-15
HUP0301828A3 (en) 2006-02-28
CZ20023427A3 (cs) 2003-11-12
EP1265609A1 (en) 2002-12-18
BG107185A (bg) 2003-05-30

Similar Documents

Publication Publication Date Title
IL151615A0 (en) Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels
PL377729A1 (pl) Sposób leczenia dysfunkcji seksualnej
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
MXPA02005737A (es) Dispositivo y metodo para tratar agua con ozono generdo mediante electrolisis del agua.
EP1541532A4 (en) WASTEWATER TREATMENT PROCEDURE ACCORDING TO THE BELIEF SLAVE METHOD WITH LINE REMOVAL TREATMENT
IL164352A0 (en) Methods for treating tweak-related conditions
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
EP1310461A4 (en) TREATMENT PROCESS FOR ORGANIC WATER
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU3894600A (en) Method of treating sexual dysfunction
EP1452492A4 (en) METHOD FOR TREATING CYANIDE LEAKAGE
GB2389455B (en) Ion implantation apparatus equipped with plasma shower and ion implantation method
IL155667A0 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
AU6605800A (en) Melanocortin receptor-3 ligands to treat sexual dysfunction
PL371604A1 (pl) Sposób obróbki wody w celu zmniejszenia stężenia jonów metali
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
EP1260486A4 (en) PROCESS FOR TREATING ORGANIC SEWAGE WATER
PL362980A1 (pl) Sposób leczenia dysfunkcji seksualnej
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
PL376350A1 (pl) Sposób obróbki szlamu
AU2001284901A1 (en) Method for treating metal contaminated water
SG110202A1 (en) Method of treating wastewater containing flouride ion
GB0011926D0 (en) Treatment of sexual dysfunction
AU2003277296A1 (en) Compositions and methods for treating sexual dysfunction

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)